rifaximin and Gastroenteritis

rifaximin has been researched along with Gastroenteritis* in 1 studies

Other Studies

1 other study(ies) available for rifaximin and Gastroenteritis

Article	Year
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Prulifloxacin, the prodrug of ulifloxacin (active component), is a newer fluoroquinolone with broad activity against enteric and nonenteric gram-negative bacilli. Ulifloxacin and other oral comparator agents were tested for activity against 582 gastroenteritis strains from global surveillance studies. Ulifloxacin was highly active against Escherichia coli, Salmonella spp., Shigella spp., Yersinia spp., Vibrio spp., Aeromonas spp., and Plesiomonas spp. (MIC(50)s and MIC(90)s, or=4 microg/ml). Ciprofloxacin exhibited similar activity but was two- to fourfold less potent. Presently approved for clinical use in certain European countries and Japan, ulifloxacin was the most active of the antimicrobial agents tested against these gastroenteritis-causing pathogens. Topics: Anti-Bacterial Agents; Diarrhea; Dioxolanes; Fluoroquinolones; Gastroenteritis; Gram-Negative Bacteria; Humans; Piperazines; Population Surveillance; Prodrugs	2009

Article

Year

Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.

Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

Prulifloxacin, the prodrug of ulifloxacin (active component), is a newer fluoroquinolone with broad activity against enteric and nonenteric gram-negative bacilli. Ulifloxacin and other oral comparator agents were tested for activity against 582 gastroenteritis strains from global surveillance studies. Ulifloxacin was highly active against Escherichia coli, Salmonella spp., Shigella spp., Yersinia spp., Vibrio spp., Aeromonas spp., and Plesiomonas spp. (MIC(50)s and MIC(90)s, or=4 microg/ml). Ciprofloxacin exhibited similar activity but was two- to fourfold less potent. Presently approved for clinical use in certain European countries and Japan, ulifloxacin was the most active of the antimicrobial agents tested against these gastroenteritis-causing pathogens.

Topics: Anti-Bacterial Agents; Diarrhea; Dioxolanes; Fluoroquinolones; Gastroenteritis; Gram-Negative Bacteria; Humans; Piperazines; Population Surveillance; Prodrugs

2009